When analysed separately, mortality risk was higher in patients on insulin (alone or in combination) than in those on insulin secretagogues in each HbA1c category, whereas it was not increased in patients treated with agents not causing hypoglycaemia and falling in the lowest HbA1c category, as compared with those on lifestyle measures only. This evidence concerns the gene INS and Hypoglycemia.